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ABSTRACT
Purpose: To determine the maximum tolerated dose (MTD), toxicities, and 
pharmacodynamics effects of sirolimus combined with oral metronomic topotecan 
and cyclophosphamide in a pediatric population.
Materials and Methods: Patients who were 1 to 30 years of age with relapsed/
refractory solid tumors (including CNS) were eligible. Patients received daily oral 
sirolimus and cyclophosphamide (25-50 mg/m2/dose) on days 1-21 and oral 
topotecan (0.8 mg/m2/dose) on days 1-14 in 28-day cycles. Sirolimus steady-state 
plasma trough concentrations of 3-7.9 ng/mL and 8-12.0 ng/mL were evaluated, 
with dose escalation based on a 3+3 phase 1 design. Biomarkers of angiogenesis 
were also evaluated.
Results: Twenty-one patients were treated (median age 18 years; range 9-30). 
Dose-limiting toxicities included myelosuppression, ALT elevation, stomatitis, 
and hypertriglyceridemia. The MTD was sirolimus with trough goal of 8-12.0 ng/
mL; cyclophosphamide 25 mg/m2/dose; and topotecan 0.8 mg/m2/dose. No 
objective responses were observed. Four patients had prolonged stable disease > 
4 cycles (range 4-12). Correlative biomarker analyses demonstrated reductions 
in thrombospondin-1 (p=0.043) and soluble vascular endothelial growth factor 
receptor-2 plasma concentrations at 21 days compared to baseline.
Conclusions: The combination of oral sirolimus, topotecan, and cyclophosphamide 
was well tolerated and biomarker studies demonstrated modulation of angiogenic 
pathways with this regimen.
INTRODUCTION
The mammalian target of rapamycin (mTOR) is 
a ubiquitous serine threonine kinase that is involved in 
the regulation of cell cycle, angiogenesis and apoptosis. 
[1] Sirolimus (also known as rapamycin) is an mTOR 
inhibitor originally approved for immunosuppression in 
patients who received renal transplants. [1] More recently, 
the mTOR pathway has been shown to be upregulated 
in many pediatric solid tumors. [2, 3] As such, mTOR 
inhibitors have been investigated in preclinical and 
clinical studies of childhood cancer. In murine models, 
single agent sirolimus has been shown to inhibit tumor 
growth in vivo in rhabdomyosarcoma, Ewing sarcoma, 
medulloblastoma, glioblastoma, neuroblastoma, and 
osteosarcoma. [4-7] Preclinical trials looking at the 
combination of sirolimus and cyclophosphamide have also 
revealed therapeutic enhancement in xenograft models of 
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pediatric solid tumors suggesting that mTOR inhibitors 
have the potential to augment the activity of conventional 
chemotherapy drugs. [8] Indeed, a recent clinical trial 
in pediatric patients with relapsed rhabdomyosarcoma 
demonstrated benefit of the combination of temsirolimus, 
vinorelbine, and cyclophosphamide. [9] In addition to 
direct effects on tumor cells, sirolimus has also been 
shown to reduce tumor angiogenesis. [7, 10, 11]
Intravenous preparations of topotecan and 
cyclophosphamide have been shown to be active in 
pediatric solid tumors, particularly Ewing sarcoma, 
neuroblastoma, and rhabdomyosarcoma. [12-16] 
Historically, this chemotherapy combination has 
been administered in pulses at 3-4 week intervals. 
However, recent data suggest that relatively low-dose, 
continuous chemotherapy (“metronomic”) administered 
over prolonged periods may be effective as well. [17] 
This approach has been hypothesized to work by 
targeting endothelial cells and thus providing a form 
of antiangiogenic therapy. [17] Phase 1 trials of oral 
cyclophosphamide and topotecan have been well tolerated 
when given in a continuous low-dose or “metronomic” 
schedule, with myelosuppression being dose limiting. [18]
The current report describes the results of a pediatric 
phase 1 study of sirolimus administered in combination 
with oral topotecan and cyclophosphamide to children 
and young adults with refractory or recurrent solid tumors. 
We pursued this combination based upon preclinical 
data demonstrating additive activity of sirolimus in 
combination with chemotherapy, the antiangiogenic 
properties associated with both metronomic chemotherapy 
and mTOR inhibition, and a desire to develop a fully oral 
combination for patients with advanced cancer who prefer 
to be treated largely at home. The primary aims of the 
study were to describe the toxicities and to recommend 
a phase 2 trough concentration of sirolimus when 
administered on a protracted schedule in combination 
with oral topotecan and cyclophosphamide. Secondary 
endpoints included an assessment of antitumor activity 
and pharmacodynamic markers of antiangiogenic effect.
RESULTS
Patient characteristics
Characteristics of the 21 enrolled patients are 
shown in Table 1. All patients had measurable disease by 
Response Evaluation Criteria in Solid Tumors (RECIST). 
One patient had received previous therapy with another 
mTOR inhibitor, ridaforolimus. The number of prior 
therapy regimens for study subjects are shown in Table 
2. In the heavily pretreated cohort, patients received a 
median of 3 prior treatment regimens (range, 2 to 13). 
Patients received a median of 1 cycle (range, 1 to 12) of 
protocol therapy (Table 2).
Dose escalation and toxicity
Dose escalation and observed dose-limiting 
toxicities (DLTs) are summarized in Table 2. Three 
patients were enrolled and evaluable on dose level 1, 
none of whom had first cycle DLT. Eight patients were 
Table 1: Patient characteristics 
All Patients
(N=21)
Median age, years (range) 18 (9-30)
Male:Female 15:6
Diagnosis
     Osteosarcoma 7
     Ewing sarcoma 3
     Rhabdomyosarcoma 3
     Brain Tumor 2a
     Neuroblastoma 1
     Other 5b
Disease Status 
     Measurable by RECIST 21 (100%)
Prior Therapy
     mTOR Inhibitor   1 (5%)
     Cyclophosphamide 9 (43%)
     Topotecan 7 (33%)
a One patient each with medulloblastoma and glioblastoma multiforme.
b One patient each with alveolar soft part sarcoma, desmosplastic small round cell 
tumor, esthesioneuroblastoma, myxofibrosarcoma, and undifferentiated sarcoma.
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subsequently enrolled on dose level 2, two of whom were 
not evaluable for DLT. One patient withdrew consent 
after the first day of protocol therapy and the second 
patient did not reach sirolimus goal trough by day 12 of 
cycle 1. Of the six patients evaluable for DLT in dose 
level 2, one patient developed dose-limiting prolonged 
thrombocytopenia during cycle 1. With 1 of 6 patients 
with first cycle DLT at dose level 2, dose level 3 was then 
evaluated. Ten patients were enrolled on dose level 3, 
six of whom were not evaluable for DLT. Three patients 
had delays in reaching target sirolimus trough levels, 
two patients had early disease progression during cycle 
1, and one patient had grade 4 thrombocytopenia during 
cycle 1 and declined appropriate laboratory studies to 
document recovery within 2 weeks of planned start of 
cycle 2 (patient subsequently went off study due to disease 
progression). Of the remaining four patients evaluable 
for DLT in dose level 3, two patients had first cycle DLT 
(grade 2 ALT elevation that did not resolve within 14 days; 
grade 4 neutropenia > 7 days). These results established 
that dose level 3 was not tolerable and the maximum 
tolerated dose (MTD) was determined to be dose level 2. 
Table 3 provides details of toxicity reported in more 
than 10% of patients of the 21 patients who received at 
least one dose of protocol therapy. Myelosuppression, 
transaminase elevation, hyperlipidemia, and electrolyte 
disturbance were the most commonly reported laboratory 
abnormalities. Mucositis and gastrointestinal symptoms 
were the most commonly reported symptoms. The 
incidence of myelosuppression did not seem to increase 
in subsequent cycles. Nonhematologic toxicity was 
uncommon in subsequent cycles of therapy, although two 
patients at dose level 2 had subsequent cycle DLT (grade 
4 hypertriglyceridemia; grade 3 stomatitis).
Four patients did not reach goal sirolimus trough 
concentrations in the first 12 days of therapy. Of the 17 
Table 2: Summary of prior treatment regimens, dose escalation, and dose-limiting toxicities (DLT)
Subject ID Number of Prior Regimens
Evaluable for Cycle 1 
DLT? Cycle 1 DLT?
Number of Cycles 
Received Description of DLT
Dose Level 1: sirolimus goal 3-7.9 ng/mL; cyclophosphamide 25 mg/m2; topotecan 0.8 mg/m2
01 11 Yes No 1
02 3 Yes No 11
03 2 Yes No 1
Dose Level 2: sirolimus goal 8-12 ng/mL; cyclophosphamide 25 mg/m2; topotecan 0.8 mg/m2
04 2 Yes Yes 1 Cycle 1 DLT, prolonged thrombocytopenia
05 4 Noa No 1
06 6 Nob No
07 4 Yes No 12
Subsequent cycle 
DLT, grade 4 
hypertriglyceridemia
08 3 Yes No 1
09 8 Yes No 4 Subsequent cycle DLT, grade 3 stomatitis
10 3 Yes No 6
11 3 Yes No 1
Dose Level 3: sirolimus goal 8-12 ng/mL; cyclophosphamide 50 mg/m2; topotecan 0.8 mg/m2
12 Unknown Yes No 1
13 3 Yes No 1
14 2 Yes Yes 1 Cycle 1 DLT, prolonged ALT elevation
15 3 Noc No 1
16 3 Nod Nod 1
17 13 Noa No 1
18 6 Noa No 2
19 8 Noa No 1
20 5 Yes Yes 3 Cycle 1 DLT, prolonged neutropenia
21 2 Noc No 1
a Sirolimus trough level not in range within 12 days of beginning protocol therapy.
b Patient withdrew consent after the first day of protocol therapy.
c Patient off study due to early progression in cycle 1.
d Patient missed labs to document timely count recovery, cannot exclude DLT.
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patients that ultimately reached sirolimus trough goal in 
cycle 1, the median time to first sirolimus trough goal 
within range was 11 days (range, 4 to 19). In cycle 1, 
the median sirolimus dose needed to achieve a trough 
concentration of 3-7.9 ng/mL was 1.05 mg/m2 (range, 1.03 
to 1.83) and the median dose need to achieve a trough 
concentration of 8-12 ng/mL was 2.76 mg/m2 (range, 1.25 
to 5.29).
Efficacy
One patient who withdrew one day after the first 
dose of protocol therapy was not evaluable for antitumor 
activity. No objective responses were observed among the 
20 remaining patients evaluable for response. Six patients 
(30%) had a best response of stable disease, including 
patients with alveolar soft part sarcoma (12 cycles), 
desmoplastic small round cell tumor (DRSCT, 11 cycles), 
osteosarcoma (6 cycles), Ewing sarcoma (4 cycles), 
esthesioneuroblastoma (3 cycles), and glioblastoma 
multiforme (2 cycles). Among the four sarcoma patients 
with prolonged stable disease ( > 4 cycles), all reached 
sirolimus trough goal in the first 12 days of cycle 1 
(median 8.5 days, range 4 to 12). At the time of this report, 
all patients have discontinued therapy due to disease 
progression. 
The estimated progression-free survival (PFS) of 
the 20 response evaluable patients is shown in Figure 1. 
The median PFS was 33 days (range, 11 to 364 days). The 
Table 3: Hematologic and nonhematologic toxicities observed in 21 patients in cycle 1 and in subsequent cycles of 
therapy with sirolimus, topotecan, and cyclophosphamide.a
Maximum Grade Observed per Patient 
During Cycle 1
Maximum Grade Observed per Patient Across 
All Subsequent Cycles (2-12)
G1 G2 G3 G4 G1 G2 G3 G4
(N=21 patients, 21 cycles) (N=6 patients, 32 cycles)
Hematologic toxicity
    Anemia 9 3 3 1 2
    Leukopenia 4 7 4 3 3 2 1
    Lymphopenia 3 3 8 1 2 3
    Neutropenia 3 3 3 4 1 1 1 1
    Thrombocytopenia 3 2 6 3 2
Nonhematologic toxicity
    Abdominal pain 4 2
    ALT elevation 5 1 1
    AST elevation 3 1
    Anorexia 2 3 1
    Bruising 3
    Constipation 4 1
    Dehydraton 2 1
    Diarrhea 8 1 3
    Dry skin 3
    Fatigue 6 2 4 1
    Headache 4 3 1
    Hypercholesterolemia 5 3
    Hyperglycemia 6 1
    Hypertension 4
    Hypertriglyceridemia 4 2 2 1 1
    Hypoalbuminemia 3
    Hypokalemia 8 2
    Mucositis 9 2 2 1
    Nausea 11 4 3 1
    Proteinuria 3 2 4
    Rash 2 1 1
    Vomiting 10 1 1 2
a Only toxicities possibly, probably, or definitely related to therapy with sirolimus, topotecan, and cyclophosphamide and 
which occurred in more than 10% of patients in cycle 1 are displayed.
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probability of PFS at 3 and 6 months was 25% (95% CI, 9 
to 45) and 15% (95% CI, 4 to 34), respectively.
Correlative studies
Nineteen patients consented to the optional 
correlative study evaluating pharmacodynamics 
angiogenesis markers. Due to a range of logistical and 
patient issues (weekends, timing of blood draws in relation 
to visits to the study center, early disease progression) 
only thirteen samples were available at baseline and six 
samples were available at day 21. Over the course of cycle 
1, median thrombospondin-1 decreased from 929 to 466 
ng/mL, median soluble vascular endothelial growth factor 
receptor-2 (sVEGFR2) decreased from 11,560 to 7,569 
pg/mL, median placental growth factor (PGF) decreased 
from 16 to 12 pg/mL, and median endoglin decreased 
from 5 to 4 ng/mL. Five patients had paired baseline and 
day 21 plasma samples available for statistical evaluation 
of potential changes in these markers (Figure 1). 
Thrombospondin-1 concentrations significantly decreased 
over cycle 1 (p = 0.043, Figure 2A). Soluble VEGFR2 
concentrations trended downward over the course of cycle 
1, but did not reach statistical significance (p = 0.057, 
Figure 2B). Endoglin and PGF levels did not significantly 
change over the course of cycle 1 (p = 0.50 and p = 0.69, 
Figures 2C and 2D). Given the small sample size, changes 
in antiangiogenesis markers were not evaluated in relation 
to efficacy.
DISCUSSION
We have developed a new regimen that combines 
metronomic chemotherapy with an oral mTOR inhibitor. 
The MTD of oral combination therapy with sirolimus, 
topotecan, and cyclophosphamide in children and young 
Table 4: Sirolimus loading and maintenance dosing by assigned dose level, age, and weight
Targeted Sirolimus Trough
3-7.9 ng/mL
Targeted Sirolimus Trough
8-12.0 ng/mL
Age < 13 years and 
Weight < 40 kg
• Initial loading dose: 3 mg/m2 on   day 1
• Initial maintenance dose: 1 mg/m2 once daily 
starting on day 2 of each cycle
• Initial loading dose: 3 mg/m2 on   day 1
• Initial maintenance dose: 1 mg/m2 divided 
twice daily starting on day 2 of each cycle
Age > 13 years or 
Weight > 40 kg
• Initial loading dose: 3 mg on day 1
• Initial maintenance dose: 1 mg once daily 
starting on day 2 of each cycle
• Initial loading dose: 6 mg on day 1
• Initial maintenance dose: 2 mg once daily 
starting on day 2 of each cycle
Figure 1: Kaplan-Meier estimated progression-free survival of 20 response-evaluable patients treated with sirolimus, 
topotecan, and cyclophosphamide therapy.
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adults with refractory and relapsed solid tumors was 
determined to be sirolimus on days 1-21 with steady-
state trough goal concentration range of 8-12.0 ng/mL; 
cyclophosphamide 25 mg/m2/dose on days 1-21; and 
topotecan 0.8 mg/m2/dose on days 1-14. This oral 3-drug 
regimen was well tolerated in this heavily pretreated 
population. No unexpected toxicities were observed. 
Overall, the most common toxicity was myelosuppression, 
which was reversible and manageable. In general, 
common symptoms of mucositis and gastrointestinal 
events, including diarrhea, nausea, and vomiting, were 
low-grade. There were no objective antitumor responses 
in this trial. Several patients with a variety of different 
tumors, including four patients with sarcoma subtypes, 
may have benefited as evidenced by stable disease for 
multiple cycles, though timing of disease evaluations may 
have over-estimated duration of disease control. Of note, 
one patient with stable disease for 12 months had alveolar 
soft part sarcoma, a histology that may show more indolent 
growth, making it difficult to draw firm conclusions about 
the role this therapy played in stabilizing her disease.
A previous phase 1 study that evaluated metronomic 
oral dosing of the combination of cyclophosphamide 
and topotecan in pediatric patients determined the MTD 
to be oral cyclophosphamide (50 mg/m2/dose) and 
oral topotecan (0.8 mg/m2/dose) administered for 14 
consecutive days in 21-28-day cycles. [18] Reversible 
hematologic dose-limiting toxicities (neutropenia and 
thrombocytopenia) were similar to those seen in this trial, 
[18] although the MTD of the cyclophosphamide in our 
trial was lower (25 mg/m2/dose), which may have been 
attributable to the addition of sirolimus; differences in 
length of administration (14 vs. 21 days on our trial); or 
overlap in elimination pathways between sirolimus and 
cyclophosphamide. While non-hematologic toxicities 
greater than grade 3 were not observed with metronomic 
cyclophosphamide and topotecan alone, the grade 3 and 
4 toxicities of mucositis and hypertriglyceridemia seen 
in patients treated on the current study are expected 
toxicities of sirolimus, or other sirolimus analogues, such 
as temsirolimus and everolimus. [19-22] Despite the 
fact that the median time to reach sirolimus steady-state 
was 11 days, subsequent cycle DLTs were uncommon 
suggesting that delays in reaching steady-state in cycle 
Figure 2: Changes in plasma A. thrombospondin-1, B. soluble VEGFR2 (sVEGFR2), C. placental growth factor (PGF), and D. 
endoglin concentrations from baseline to day 21 ± 2 of cycle 1 in five individual patients with paired samples.
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1 did not result in falsely concluding that a higher dose 
level was tolerable. While our study did not investigate 
other schedules of metronomic therapy, a schedule of oral 
cyclophosphamide and topotecan administered for 7 days 
every other week may have maximized drug exposure 
while decreasing hematologic toxicities.
In clinical trials, sirolimus has been combined 
with various cytotoxic chemotherapy agents, including 
intensive AML induction chemotherapy (mitoxantrone, 
etoposide, cytarabine); [23] gemcitabine; [24] vinblastine; 
[25] and paclitaxel. [26] Of particular interest, in a phase 
2 trial of advanced sarcomas, patients received daily 
sirolimus (4 mg/dose) and oral cyclophosphamide (200 
mg/dose) administered daily for 7 days every other week 
in 28-day cycles. Myelosuppression was a common 
toxicity reported with this combination. [27] Serious 
adverse events attributed to this therapy occurred in 11% 
of patients and included infection, pneumonitis, and 
thrombosis. [27] Patients were followed for a minimum 
of 6 months and 21% (10/47) of evaluable patients were 
progression-free for at least 6 months. [27] The 6-month 
PFS in patients receiving sirolimus and cyclophosphamide 
is higher than what was found in our study, which may 
be attributable to differences in the patient populations 
between the two clinical trials.
We examined correlative biomarkers in this 
trial to improve our understanding of the effect of this 
combination on angiogenesis pathways. While plasma 
thrombospondin, endoglin, PGF, and soluble VEGFR2 
levels have been used as angiogenesis biomarkers in many 
previous studies of VEGF receptor tyrosine kinase (RTK) 
inhibitors, [28] little work has evaluated these markers in 
patients receiving mTOR inhibitors and/or metronomic 
chemotherapy. As in previous studies with RTK inhibitors, 
our combination therapy resulted in decreases in soluble 
VEGFR2 concentrations. [28] In addition, our study 
showed a significant decrease in thrombospondin-1 
concentration, similar to an adult study of metronomic 
cyclophosphamide in advanced malignancies. [29, 30] 
Thrombospondin-1 is a modulator of angiogenesis and 
is hypothesized to play a role in mediating angiogenic 
activity of metronomic chemotherapy. [31] Previous 
studies of metronomic chemotherapy in pediatric patients 
showed that an elevated baseline thrombospondin-1 
concentration may correlate with clinical benefit. [32, 
33] Our sample size precluded a similar analysis in this 
study. We did not detect changes in PGF and endoglin in 
this study. The clinical significance of these changes in 
potential surrogate markers requires further evaluation.
One limitation of our study was difficulty in 
reaching sirolimus goal steady-state concentrations in 
a timely manner. Four out of 21 patients (19%) were 
deemed inevaluable for cycle 1 DLT assessment due to 
delays in reaching sirolimus goal trough concentrations 
by day 12 of treatment. This experience has been reported 
by other groups. For example, Morgenstern and colleagues 
reported difficulty in achieving target sirolimus trough 
concentration in the range of 10-15 ng/mL in pediatric 
patients treated with sirolimus and vinblastine. [25] In 
their study, sirolimus trough levels were monitored weekly 
during the first cycle and then at the start of subsequent 
cycles once in target range. Overall, only 10 of 14 
patients achieved the target concentration after a mean 
of 3 weeks (range, 1 to 8 weeks). [25] Of all measured 
sirolimus concentrations, 27% were within the target 
range, whereas 14% were > 15 ng/mL and 59% were < 10 
ng/mL. [25] This considerable inter-patient variability in 
dose-concentration relationship is consistent with previous 
reports of the variable pharmacokinetics of sirolimus. 
[34] Likewise in the current study, we observed a wide 
range of sirolimus doses needed to achieve the desired 
trough concentrations. These findings suggest that newer 
sirolimus analogues (“rapalogues”) with more consistent 
pharmacokinetic properties might be better suited in the 
context of a study targeting specific trough concentrations. 
In conclusion, the combination of oral sirolimus, 
topotecan, and cyclophosphamide was well tolerated 
in this heavily pre-treated population. However, in 
the context of this phase 1 study, it is unclear if the 
addition of sirolimus improved on the anti-tumor effect 
of metronomic cyclophosphamide and topotecan which 
previously demonstrated some activity against recurrent 
pediatric solid tumors (partial response in one patient 
with neuroblastoma and a patient with medulloblastoma 
with prolonged stable disease). [18] The convenience 
associated with oral administration, evidence of 
modulation of angiogenesis pathways, and our findings of 
several patients with prolonged stable disease suggest that 
this regimen may be considered for patients with advanced 
sarcoma seeking a palliative regimen. 
MATERIALS AND METHODS
Patients
Patients were eligible for participation if they were 
12 months to 30 years of age, had histologic diagnosis 
of solid tumor (including brain tumors) with measurable 
or evaluable disease, and had no known curative options. 
Patients were required to have a Karnofsky (age > 16 
years) or Lansky (age < 16 years) performance score of 
50 or more and to have recovered from previous therapy. 
Patients previously treated with sirolimus, topotecan, or 
cyclophosphamide as single agents were eligible. Patients 
previously treated with two of the three drugs were 
eligible, though patients previously treated with all three 
agents in combination were excluded. Patients previously 
treated with sirolimus analogues (e.g. temsirolimus, 
everolimus, or ridaforolimus) were also eligible. Patients 
were required to have adequate baseline bone marrow 
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(absolute neutrophil count > 750/μL; platelet count > 
75,000/μL for patients without bone marrow involvement 
or platelet count > 25,000/μL for those with known bone 
marrow metastatic disease), renal, hepatic, pulmonary, 
and central nervous system function according to defined 
protocol criteria. Patients were required to have serum 
fasting triglyceride and cholesterol levels both < 300 mg/
dL.
Exclusion criteria included: pregnancy or 
breastfeeding; concurrent use of strong CYP3A4 inducers 
or inhibitors; concurrent use of enzyme-inducing 
anticonvulsants; concurrent use of corticosteroids not on 
a stable or decreasing dose for 7 days prior to enrollment; 
uncontrolled infections; or history of allergic reaction to 
compounds of similar composition to sirolimus, topotecan, 
or cyclophosphamide.
The protocol was approved by the University of 
California, San Francisco Committee on Human Research. 
Written informed consent (and assent when applicable) 
was obtained for all patients. This trial was registered with 
ClinicalTrials.gov number NCT01670175.
Treatment and evaluations
The dose escalation schema is summarized in 
Table 2. Patients received daily oral sirolimus and 
cyclophosphamide on days 1-21 in a 28-day cycle. This 
was combined with oral topotecan given once daily on 
days 1-14. Sirolimus dosing was based on steady-state 
plasma trough concentrations with a starting goal level of 
3-7.9 ng/mL in dose level 1 and goals levels of 8-12.0 ng/
mL in subsequent dose levels. The topotecan dose was 0.8 
mg/m2/dose in all dose levels. The cyclophosphamide dose 
was 25 mg/m2/dose for dose levels 1 and 2 and 50 mg/m2/
dose in dose level 3. Calculations for body surface area 
were capped at 2 m2 for cyclophosphamide and topotecan. 
Initial sirolimus loading and maintenance doses were 
based on the patient’s weight, age, and assigned dose level 
(Table 4). Of note, sirolimus is available commercially as 
an oral solution (1 mg/mL) and in tablet form (1 mg and 
2 mg tablets). Both formulations were available for study 
subjects and were chosen at the discretion of the treating 
physician. Sirolimus trough levels were drawn 3-4 days 
following a loading dose. If the level was in the desired 
range, a repeat level was drawn 3-4 days following the 
initial level. Once a stable level within the goal range was 
obtained two times in a row, levels were obtained once per 
cycle unless a change in concomitant medication or liver 
function had the potential to impact sirolimus metabolism. 
Adjustments to sirolimus maintenance and loading doses 
were based on calculations provided in the package insert. 
[35] Patients without disease progression or unacceptable 
toxicity could receive up to two years of therapy.
Patients had routine physical examinations and 
surveillance laboratory testing to evaluate for toxicity. 
Toxicities were graded according to the National Cancer 
Institute (NCI) Common Terminology Criteria, version 
4.0. DLT was defined as any of the following that were 
attributed as at least possibly related to study therapy: 
grade 4 neutropenia with fever or grade 4 neutropenia for 
> 7 days; platelet transfusion for a platelet count < 10 x 
109/L or for clinical bleeding on 2 separate days within 
a 7 day period; myelosuppression that delayed start of 
subsequent cycle by > 14 days; any grade 3 or 4 non-
hematological toxicity with the specific exclusion of grade 
3 nausea and vomiting < 3 days, grade 3 diarrhea < 3 days, 
grade 3 mucositis or stomatitis < 3 days, grade 3 alanine/
aspartate aminotransferase (ALT/AST) that returned to 
grade < 1 or baseline prior to the start of the next treatment 
cycle, grade 3 fever, grade 3 infection, grade 3 electrolyte 
abnormalities responsive to oral supplementation within 
7 days, grade 3 or 4 hypertriglyceridemia that returned 
to grade < 2 within 7 days of drug interruption, grade 3 
or 4 hypercholesterolemia responsive to lipid lowering 
medication within 35 days, and grade 3 hyperglycemia 
that returned to < grade 2 or baseline prior to start of next 
treatment cycle. 
Patients underwent disease evaluation at baseline 
and then at the end of cycles 1 and 3, and then every 
third cycle. For patients with measurable disease, tumor 
response was evaluated by RECIST. [36] For patients 
with neuroblastoma, a modification of the International 
Neuroblastoma Response Criteria was used that utilized 
meta-iodobenzylguanidine (MIBG) response by Curie 
score and RECIST for soft tissue disease. [37, 38]
Biomarker studies
Plasma was obtained at baseline and day 21 ± 
2 of cycle 1 in consenting patients to assess the impact 
of study therapy on biomarkers of angiogenesis. 
Thrombospondin-1, endoglin, PGF, and sVEGFR2 levels 
were measured by ELISA using commercially available 
kits (R&D Systems, Minneapolis, MN).
Dose escalation strategy and statistical methods
The primary endpoint for determining dose 
escalation was DLT attributed to study therapy in cycle 
1. A standard 3 + 3 phase 1 dose escalation design was 
utilized, with escalation starting at dose level 1. Patients 
were considered evaluable for dose escalation decisions 
if: they (1) received > 17 of the 21 of the planned doses 
of sirolimus and cyclophosphamide AND (2) received 
> 11 of the 14 of the planned doses of topotecan AND 
were followed until they met toxicity criteria to proceed to 
cycle 2. In addition, patients who experienced DLT at any 
time after the first doses of medication were considered 
evaluable. Lastly, patients must have had at least one 
sirolimus trough level in goal range within the first 12 days 
of cycle 1 to be considered evaluable for dose escalation/
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de-escalation purposes at that dose level.
Changes in angiogenesis biomarkers obtained at 
baseline and at the end of cycle 1 were assessed using 
Wilcoxon signed rank test for all paired data available 
at baseline and day 21 ± 2. PFS was defined as the time 
from enrollment to first occurrence of disease progression 
or death. Patients without an event were censored at 
the time of last patient contact. We estimated PFS with 
the Kaplan-Meier method and reported the median PFS 
and PFS at 3 and 6 months for the treatment group. All 
statistical analyses were performed using Stata, version 13 
(StataCorp, College Station, TX).
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